Cargando…

295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer

OBJECTIVES/GOALS: Our objective is to establish a proteomic protein labeling method from tumor tissue and blood samples obtained from patients undergoing surgery for pancreatic cancer in Puerto Rico. Our goal is to discover potential biomarkers in the patient tumor/blood samples that are not express...

Descripción completa

Detalles Bibliográficos
Autores principales: Santiago-Gonzalez, Juan C., Miranda, Eric, Hernandez, Pedro, Serrano, Horacio, Hallman, Deana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129717/
http://dx.doi.org/10.1017/cts.2023.350
_version_ 1785030811645378560
author Santiago-Gonzalez, Juan C.
Miranda, Eric
Hernandez, Pedro
Serrano, Horacio
Hallman, Deana
author_facet Santiago-Gonzalez, Juan C.
Miranda, Eric
Hernandez, Pedro
Serrano, Horacio
Hallman, Deana
author_sort Santiago-Gonzalez, Juan C.
collection PubMed
description OBJECTIVES/GOALS: Our objective is to establish a proteomic protein labeling method from tumor tissue and blood samples obtained from patients undergoing surgery for pancreatic cancer in Puerto Rico. Our goal is to discover potential biomarkers in the patient tumor/blood samples that are not expressed in normal control samples obtained from potential organ donors. METHODS/STUDY POPULATION: A pilot study with ten patients undergoing surgery for pancreatic cancer will obtain tumor tissue and blood samples. Protein extracts isolated from tissue/cells will be reduced, alkylated, and digested overnight. Samples will be labeled with TMT reagents and mixed before fractionation and cleanup. Labeled samples will be analyzed with a high-resolution Orbitrap LC-MS/MS before data analysis to identify peptides and quantify the reporter ions. The altered proteins will be analyzed by ELISA to confirm their presence. The protein arrangements will be compared with results from proteomic profile banks to assess their prevalence. As controls, parallel protein analyses will be performed on normal tissue/blood samples from organ donors, facilitated by our local organ procurement organization. RESULTS/ANTICIPATED RESULTS: We anticipate finding proteogenomic material defining PC and new proteomic subtypes not previously described in this population. In addition, studying protein overexpression and underexpression can identify relevant genes and potential biomarkers. We hypothesize that PC in the Hispanic population will show slight variations in tumor protein expression than in other populations, which could lead to the discovery of a new Hispanic-specific biomarker. DISCUSSION/SIGNIFICANCE: We expect to provide essential information that will influence the next steps in developing future screening tests. Identifying specific proteins with the potential to become a preventive test should eventually lead to a reduction in morbidity and mortality of PC. The results of this work should lay the foundation that can guide future research.
format Online
Article
Text
id pubmed-10129717
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-101297172023-04-26 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer Santiago-Gonzalez, Juan C. Miranda, Eric Hernandez, Pedro Serrano, Horacio Hallman, Deana J Clin Transl Sci Precision Medicine/Health OBJECTIVES/GOALS: Our objective is to establish a proteomic protein labeling method from tumor tissue and blood samples obtained from patients undergoing surgery for pancreatic cancer in Puerto Rico. Our goal is to discover potential biomarkers in the patient tumor/blood samples that are not expressed in normal control samples obtained from potential organ donors. METHODS/STUDY POPULATION: A pilot study with ten patients undergoing surgery for pancreatic cancer will obtain tumor tissue and blood samples. Protein extracts isolated from tissue/cells will be reduced, alkylated, and digested overnight. Samples will be labeled with TMT reagents and mixed before fractionation and cleanup. Labeled samples will be analyzed with a high-resolution Orbitrap LC-MS/MS before data analysis to identify peptides and quantify the reporter ions. The altered proteins will be analyzed by ELISA to confirm their presence. The protein arrangements will be compared with results from proteomic profile banks to assess their prevalence. As controls, parallel protein analyses will be performed on normal tissue/blood samples from organ donors, facilitated by our local organ procurement organization. RESULTS/ANTICIPATED RESULTS: We anticipate finding proteogenomic material defining PC and new proteomic subtypes not previously described in this population. In addition, studying protein overexpression and underexpression can identify relevant genes and potential biomarkers. We hypothesize that PC in the Hispanic population will show slight variations in tumor protein expression than in other populations, which could lead to the discovery of a new Hispanic-specific biomarker. DISCUSSION/SIGNIFICANCE: We expect to provide essential information that will influence the next steps in developing future screening tests. Identifying specific proteins with the potential to become a preventive test should eventually lead to a reduction in morbidity and mortality of PC. The results of this work should lay the foundation that can guide future research. Cambridge University Press 2023-04-24 /pmc/articles/PMC10129717/ http://dx.doi.org/10.1017/cts.2023.350 Text en © The Association for Clinical and Translational Science 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Precision Medicine/Health
Santiago-Gonzalez, Juan C.
Miranda, Eric
Hernandez, Pedro
Serrano, Horacio
Hallman, Deana
295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer
title 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer
title_full 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer
title_fullStr 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer
title_full_unstemmed 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer
title_short 295 Identification of Proteomic Biomarkers in Puerto Ricans with Pancreatic Cancer
title_sort 295 identification of proteomic biomarkers in puerto ricans with pancreatic cancer
topic Precision Medicine/Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129717/
http://dx.doi.org/10.1017/cts.2023.350
work_keys_str_mv AT santiagogonzalezjuanc 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer
AT mirandaeric 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer
AT hernandezpedro 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer
AT serranohoracio 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer
AT hallmandeana 295identificationofproteomicbiomarkersinpuertoricanswithpancreaticcancer